| NCT ID | NCT07219693 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Semler Scientific |
| Condition | To Assess Cardiovascular Function |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-08-21 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2025-08-21 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the finger during a forced expiration ("FE"). The study examines whether Echo-measured GLS values greater than -16% correlate with abnormal responses during FE as measured by QuantaFlo HD.
Eligibility Criteria
Inclusion Criteria: * Male and female adult (≥ age 22) subjects with a minimum of 1 of the following: * A history of Cardiovascular Diseasei or PAD * Recorded history of at least two of the following * Hypertension * Diabetes * Hyperlipidemia Exclusion Criteria: * Unable to safely perform a forced expiration, or unable to obtain a technically adequate FE test result * Subjects with a pacemaker or ICD with pacemaker function * Terminal advanced illness * Recent cardiothoracic surgery (within 12 months) * Retinal eye disease with anticoagulants * History of eye surgery, within 90 days * Uncontrolled hypertension \>180 mmHg systolic pressure or \>100 mmHg diastolic pressure * Subjects with severe tremors
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07219693 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, studying To Assess Cardiovascular Function. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07219693 currently recruiting?
Yes, NCT07219693 is actively recruiting participants. Contact the research team at gparker@semlerscientific.com for enrollment information.
Where is the NCT07219693 trial being conducted?
This trial is being conducted at Tucson, United States.
Who is sponsoring the NCT07219693 clinical trial?
NCT07219693 is sponsored by Semler Scientific. The trial plans to enroll 600 participants.